Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial
Primary result · Mean change in finger pain (100 mm VAS)Result — go to the resultBetween-group difference −0.4 mm 95% CI −7.6 to 6.7Authors' conclusion
In people with painful hand osteoarthritis, treatment with 0.5 mg of colchicine twice day for 12 weeks did not effectively relieve pain, and treatment with colchicine was associated with more adverse events.
Study context
- Population
- Adults with symptomatic hand OA and finger pain ≥40 mm on a 100 mm VAS, outpatient clinic in Denmarkall completed the study
- Participants
- 100 adults
- Comparison
- Colchicine 0.5 mg orally twice a day for 12 weeks vs placebo
- Colchicinen = 50
- Placebon = 50reference
- Primary endpoint
- Change from baseline in target hand finger pain (100 mm VAS; pre-specified MCID 15 mm), ITT population
- Follow-up
- Week 12
Methodological detailssingle-centre, double-blind, placebo-controlled
- Single-centre
- Double-blind
- Placebo-controlled
Primary result
Mean change in finger pain (100 mm VAS)
Between-group difference
−0.4 mm
95% CI −7.6 to 6.7
P = 0.90
Change by group
Colchicine
−13.9
mean · SE 2.8 · mm
Placebo
−13.5
mean · SE 2.8 · mm
Colchicinevs Placebo
between-group difference −0.4 mm (95% CI −7.6 to 6.7); P = 0.90
As reported in the abstract
Safety
Adverse events (participants with ≥1 AE) · week 12 · intention-to-treat
Adverse events Colchicine 76 · Placebo 42
Events
| Outcome | Colchicine | Placebo |
|---|---|---|
| Serious adverse events · week 12 | 1 | 2 |
- Serious adverse events: Colchicine: migraine attack leading to hospital admission; Placebo: cholecystitis and elevated alanine aminotransferase, in the same patient
Original publication
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. Published 4 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →